M. Morgan

Polyclonal anti-PSA is more sensitive but less specific than monoclonal anti-PSA: Implications for diagnostic prostatic pathology.

M. Varma, P. Tamboli, M. Amin, 2002, American journal of clinical pathology.

High molecular weight cytokeratin antibody (clone 34βE12): a sensitive marker for differentiation of high‐grade invasive urothelial carcinoma from prostate cancer

M. Varma, M. Amin, B. Jasani, 2003, Histopathology.

High‐molecular‐weight cytokeratin antibody (clone 34βE12) as a urothelial marker: a note of caution

M. Varma, M. Amin, B. Jasani, 2004, Histopathology.

Impact of HER2 copy number in IHC2+/FISH-amplified breast cancer on outcome of adjuvant trastuzumab treatment in a large UK cancer network

B. Jasani, M. Brunelli, P. Barrett-Lee, 2014, British Journal of Cancer.

Evaluation of automated silver‐enhanced in situ hybridization (SISH) for detection of HER2 gene amplification in breast carcinoma excision and core biopsy specimens

S. Shousha, B. Jasani, D. Peston, 2009, Histopathology.

Prostate specific antigen (PSA) and prostate specific acid phosphatase (PSAP) immunoreactivity in benign seminal vesicle\ejaculatory duct epithelium: a potential pitfall in the diagnosis of prostate cancer in needle biopsy specimens

M. Varma, B. Jasani, M. Morgan, 2004, Histopathology.